natgillin/translations-raw huggingface dataset:
For patients with moderate renal impairment (creatinine clearance ≥ 30 to ≤ 50 mL/min), one-half of the recommended dose of alogliptin should be administered (12.5 mg once daily; see section 5.2).
Pri bolnikih z zmerno okvaro ledvic (kreatininski očistek ≥ 30 do ≤ 50 ml/min) je treba uporabiti polovico priporočenega odmerka alogliptina (12,5 mg enkrat na dan, glejte poglavje 5.2).
For patients with moderate renal impairment (creatinine clearance ≥ 30 to ≤ 50 mL/min), one-half of the recommended dose of alogliptin should be administered.
Pri bolnikih z zmerno okvaro ledvic (kreatininski očistek ≥ 30 do ≤ 50 ml/min) je treba uporabiti polovico priporočenega odmerka alogliptina.
For patients with moderate to severe hepatic impairment, the 92/22 micrograms dose should be used and patients should be monitored for systemic corticosteroid-related adverse reactions (see section 5.2).
Pri bolnikih z zmerno do hudo okvaro jeter je treba uporabiti odmerek 92/22 mikrogramov in bolnike je treba kontrolirati glede sistemskih neželenih učinkov, povezanih s kortikosteroidi (glejte poglavje 5.2).
For patients with more than one event contributing to the composite endpoint, only the first event was reported (e.g., if a subject experienced both a DVT and then a PE, only the DVT was reported)
Pri bolnikih z več kot enim dogodkom, ki je prispeval k sestavljenemu opazovanemu dogodku, so poročali samo o enem dogodku (npr. če je imel bolnik GVT in potem PE, so poročali samo o GVT).
For patients with more than one event contributing to the composite endpoint, only the first event was reported (eg, if a subject experienced both a DVT and then a PE, only the DVT was reported)
Pri bolnikih z več kot enim dogodkom, ki je prispeval k sestavljenemu opazovanemu dogodku, so poročali samo o enem dogodku (npr. če je imel bolnik GVT in potem PE, so poročali samo o GVT).
For patients with normal baseline CA 19-9 levels the survival HR was 1.07 (95% CI 0.692, 1.661).
Pri bolnikih z normalno izhodiščno ravnijo CA 19-9 je bilo razmerje tveganja za preživetje 1,07 (95 % IZ 0,692; 1,661).
For patients with normal baseline serum creatinine (< 1.4 mg/dl or < 124 µmol/l), an increase of 0.5 mg/dl or 44 µmol/l;
pri bolnikih z normalnim izhodiščnim serumskim kreatininom (< 1,4 mg/dl ali < 124 μmol/l), zvišanje za 0,5 mg/dl ali 44 μmol/l;
For patients with normal baseline serum creatinine (< 1.4 mg/dl or < 124 μmol/l), an increase of 0.5 mg/dl or 44 μmol/l;
pri bolnikih z normalnimi vrednostmi izhodiščnega serumskega kreatinina (< 1,4 mg/dl ali
For patients with NSCLC other than predominantly squamous cell histology (n = 430, independently reviewed population) median PFS was 4.4 months for the pemetrexed arm and 1.8 months for the placebo arm, hazard ratio = 0.47 (95 % CI = 0.37 - 0.60, p = 0.00001).
Za bolnike z NSCLC , ki nima pretežno ploščatocelične histologije (n = 430, neodvisno pregledana populacija) je bila mediana preživetja brez napredovanja 4,4 mesece za skupino s pemetreksedom in 1,8 meseca za skupino s placebom, razmerje tveganja = 0,47, 95% CI: 0,37 - 0,60, p = 0,00001).
For patients with NSCLC other than predominantly squamous cell histology (n = 430, independently reviewed population) median PFS was 4.4 months for the pemetrexed arm and 1.8 months for the placebo arm, hazard ratio = 0.47 (95 % CI = 0.37 - 0.60, p = 0.00001).
Za bolnike z NSCLC , ki nima pretežno ploščatocelične histologije (n = 430, neodvisno pregledana populacija) je bila mediana preživetja brez napredovanja 4,4 mesece za skupino s pemetreksedom in 1,8 meseca za skupino s placebom, razmerje tveganja = 0,47, 95% CI: 0,37-0,60, p = 0,00001).
For patients with NSCLC other than predominantly squamous cell histology (N = 430, independently reviewed population) median PFS was 4.4 months for the pemetrexed arm and 1.8 months for the placebo arm, hazard ratio = 0.47 (95% CI = 0.37-0.60, p = 0.00001).
Za bolnike z NSCLC , ki nima pretežno ploščatocelične histologije (n = 430, neodvisno pregledana populacija) je bila mediana preživetja brez napredovanja 4,4 mesece za skupino s pemetreksedom in 1,8 meseca za skupino s placebom, razmerje tveganja = 0,47, 95% CI: 0,37-0,60, p = 0,00001).
For patients with NVAF treated for prevention of stroke and SEE and for DVT/PE patients, concomitantly receiving dabigatran etexilate and verapamil, the dose of Pradaxa should be reduced to 220 mg taken as one 110 mg capsule twice daily (see section 4.2).
Pri bolnikih z NVAF, pri katerih preprečujemo možgansko kap in sistemske embolične dogodke in sočasno prejemajo dabigatran eteksilat in verapamil, je treba odmerek zdravila Pradaxa zmanjšati na 220 mg, to je 110 mg dvakrat dnevno (glejte poglavje 4.2)
For patients with observed worsening of liver function tests considered related to treatment with Stivarga (i.e. where no alternative cause is evident, such as post-hepatic cholestasis or disease progression), the dose modification and monitoring advice in Table 2 should be followed (see section 4.2).
Pri bolnikih z opaženim poslabšanjem izvidov preiskav delovanja jeter, za katera se meni, da so posledica zdravljenja z zdravilom Stivarga (tj. ko ni očitnega drugega vzroka, npr. posthepatična holestaza ali napredovanje bolezni), je treba upoštevati priporočila za spremembo odmerka in spremljanje v preglednici 2 (glejte poglavje 4.2).
For patients with operable node-negative breast cancer, adjuvant treatment should be resticted to patients eligible to receive chemotherapy according to internationally established crieteria from primary therapy of early breast cancer (see section 5.1).
Pri bolnikih z operabilnim rakom dojke z negativnimi bezgavkami mora biti adjuvantno zdravljenje omejeno na bolnike, primerne za prejemanje kemoterapije v skladu z mednarodno sprejetimi merili za primarno zdravljenje zgodnjega raka dojke (glejte poglavje 5.1).
For patients with partial DPD deficiency (such as those with heterozygous mutations in the DPYD gene) and where the benefits of Xeloda are considered to outweigh the risks (taking into account the suitability of an alternative non-fluoropyrimidine chemotherapeutic regimen), these patients must be treated with extreme caution and frequent monitoring with dose adjusment according to toxicity.
Bolnike z delnim pomanjkanjem DPD (kot so tisti s heterozigotnimi mutacijami v genu DPYD) za katere smatramo, da koristi zdravila Xeloda odtehtajo tveganja (upoštevaje primernost druge ne- fluoropirimidinske sheme kemoterapije), je treba zdraviti izredno previdno in jih pogosto spremljati ter prilagoditi odmerek glede na toksičnost.
For patients with Peyronie’s disease, Xiapex is given for up to 4 treatment cycles each lasting about 6 weeks.
Bolnikom s Peyroniejevo boleznijo se zdravilo Xiapex daje največ štiri cikle zdravljenja, od katerih vsak traja približno šest tednov.
For patients with RCC and severe hepatic impairment (total bilirubin >3 times ULN with any abnormality of AST, or as defined by Child-Pugh Class C), the recommended dose for patients who have baseline platelets 100 x 109/l is 10 mg intravenous once a week infused over a
Za bolnike z RCC in hudo okvaro jeter (celotni bilirubin nad trikrat višji od zgornje meje normalnih vrednosti, ne glede na kakršnekoli nepravilnosti AST, ali razred C po Child-Pughovi lestvici) je priporočeni odmerek za bolnike, ki imajo izhodiščno koncentracijo
For patients with RCC and severe hepatic impairment, the recommended dose for patients who have baseline platelets 100 x 109/l is 10 mg intravenous once a week infused over a 30-60 minute period (see section 5.2).
Za bolnike z RCC in hudo okvaro jeter je priporočeni odmerek za bolnike, ki imajo izhodiščno koncentracijo trombocitov  100 x 109/l, 10 mg intravensko enkrat na teden, infundiran v obdobju 30-60 minut (glejte poglavje 5.2).
For patients with renal angiomyolipoma and severe impairment of liver function Votubia is only recommended if the desired benefit outweighs the risk.
Pri bolnikih z ledvičnim angiomiolipomom in hudo okvaro delovanja jeter je zdravilo Votubia priporočljivo samo, če želene koristi zdravila odtehtajo z njim povezana tveganja.
For patients with renal failure, hepatic impairment or failure, children and pregnant women, see section 4.3. The concomitant administration of Agenerase oral solution with disulfiram or other medicinal products that reduce alcohol metabolism (e.g. metronidazole), or preparations that contain alcohol (e.g. ritonavir oral solution) or additional propylene glycol is contraindicated (see sections 4.3and 4.5).
Glede bolnikov z odpovedjo ledvic, bolnikov z oslabljenim delovanjem ali odpovedjo jeter, otrok in nosečnic glejte poglavje 4.3. Uporaba peroralne raztopine Agenerase sočasno z disulfiramom ali drugimi zdravili, ki zmanjšujejo presnovo alkohola (npr. metronidazol), s pripravki z alkoholom (npr. peroralna raztopina ritonavirja) ali s pripravki z dodatnim propilenglikolom je kontraindicirana (glejte poglavji 4.3 in 4.5).
For patients with renal impairment, no dose adjustment for linagliptin is required.
Bolnikom z ledvično okvaro odmerka linagliptina ni treba prilagoditi.
For patients with renal or hepatic impairment colchicine with boosted PREZISTA is contraindicated (see section 4.3).
Pri bolnikih z ledvično ali jetrno okvaro je kombinacija kolhicina in okrepljenega zdravila PREZISTA kontraindicirana (glejte poglavje 4.3).
For patients with serum bilirubin levels >ULN and/or ALT and AST >3.5 times the ULN concurrent with serum alkaline phosphatase levels >6 times the ULN, no dose-reduction can be recommended and docetaxel should not be used unless strictly indicated.
Pri bolnikih, ki imajo serumski bilirubin > ULN in/ali ALT in AST > 3,5-kratno ULN ter hkrati alkalno fosfatazo > 6-kratno ULN, ni mogoče priporočiti zmanjšanja odmerka; pri teh bolnikih se docetaksela ne sme uporabljati, če ni strogo indiciran.
For patients with serum bilirubin levels >ULN and/or ALT and AST >3.5 times the ULN concurrent with serum alkaline phosphatase levels >6 times the ULN, no dose-reduction can be recommended and docetaxel should not be used unless strictly indicated.
Pri bolnikih, ki imajo serumski bilirubin > ZMRO in/ali ALT in AST > 3,5-kratno ZMRO ter hkrati alkalno fosfatazo > 6-kratno ZMRO, ni mogoče priporočiti zmanjšanja odmerka; pri teh bolnikih se docetaksel ne sme uporabljati, če ni izrecno indiciran.
For patients with severe hepatic impairment, a reduction of the temsirolimus dose to 10 mg is recommended to provide temsirolimus plus sirolimus exposures in blood (mean AUCsum approximately 6510 ng·h/ml; n=7), which approximate to those following the
Pri bolnikih s hudimi okvarami jeter je priporočljivo zmanjšanje odmerka temsirolimusa na 10 mg.
For patients with severe renal impairment (CrCl < 30 mL/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis, the dose of Januvia is 25 mg once daily.
Za bolnike s hudo ledvično okvaro (kreatininski očistek < 30 ml/min) in bolnike s končno ledvično odpovedjo (ESRD – end-stage renal disease), ki potrebujejo hemodializo ali peritonealno dializo, je odmerek zdravila Januvia 25 mg enkrat na dan.
For patients with severe renal impairment (CrCl < 30 mL/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis, the dose of Ristaben is 25 mg once daily.
Za bolnike s hudo ledvično okvaro (kreatininski očistek < 30 ml/min) in bolnike s končno ledvično odpovedjo (ESRD – end-stage renal disease), ki potrebujejo hemodializo ali peritonealno dializo, je odmerek zdravila Ristaben 25 mg enkrat na dan.
For patients with severe renal impairment (CrCl < 30 mL/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis, the dose of TESAVEL is 25 mg once daily.
Za bolnike s hudo ledvično okvaro (kreatininski očistek < 30 ml/min) in bolnike s končno ledvično odpovedjo (ESRD – end-stage renal disease), ki potrebujejo hemodializo ali peritonealno dializo, je odmerek zdravila TESAVEL 25 mg enkrat na dan.
For patients with severe renal impairment (CrCl < 30 mL/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis, the dose of Xelevia is 25 mg once daily.
Za bolnike s hudo ledvično okvaro (kreatininski očistek < 30 ml/min) in bolnike s končno ledvično odpovedjo (ESRD – end-stage renal disease), ki potrebujejo hemodializo ali peritonealno dializo, je odmerek zdravila Xelevia 25 mg enkrat na dan.
For patients with severe renal impairment (CrCl <30 mL/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis, the dose of Januvia is 25 mg once daily.
Za bolnike s hudo ledvično okvaro (kreatininski očistek < 30 ml/min) in bolnike s končno ledvično odpovedjo (ESRD – end-stage renal disease), ki potrebujejo hemodializo ali peritonealno dializo, je odmerek zdravila Januvia 25 mg enkrat na dan.
For patients with severe renal impairment (CrCl <30 mL/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis, the dose of TESAVEL is 25 mg once daily.
Za bolnike s hudo ledvično okvaro (kreatininski očistek < 30 ml/min) in bolnike s končno ledvično odpovedjo (ESRD – end-stage renal disease), ki potrebujejo hemodializo ali peritonealno dializo, je odmerek zdravila TESAVEL 25 mg enkrat na dan.
For patients with severe renal impairment (CrCl <30 mL/min) or with end-stage renal disease (ESRD) requiring haemodialysis or peritoneal dialysis, the dose of Xelevia is 25 mg once daily.
Za bolnike s hudo ledvično okvaro (kreatininski očistek < 30 ml/min) in bolnike s končno ledvično odpovedjo (ESRD – end-stage renal disease), ki potrebujejo hemodializo ali peritonealno dializo, je odmerek zdravila Xelevia 25 mg enkrat na dan.
For patients with severe renal impairment (creatinine clearance < 30 mL/min) or end-stage renal disease requiring dialysis, one-quarter of the recommended dose of alogliptin should be administered (6.25 mg once daily).
Pri bolnikih s hudo okvaro ledvic (kreatininski očistek < 30 ml/min) in bolnikih s končno ledvično odpovedjo, ki potrebujejo dializo, je treba uporabiti četrtino priporočenega odmerka alogliptina (6,25 mg enkrat na dan).
For patients with severe renal impairment (estimated creatinine clearance < 30 ml/min), the recommended dose of CHAMPIX is 1 mg once daily.
Priporočeni odmerek zdravila CHAMPIX pri bolnikih s hudo okvaro ledvic (ocenjeni očistek kreatinina < 30 ml/min) je 1 mg enkrat na dan.
For patients with severe renal impairment 10 mg is the maximum recommended dose.
Pri bolnikih s hudo okvaro ledvic je najvišji priporočeni odmerek 10 mg.
For patients with severe renal impairment, see section 4.3. ee section 4.2 for information on patients with mild or moderate renal dysfunction.
Za bolnike s hudo okvarjenim delovanjem ledvic glejte poglavje 4.3. Za podatke o bolnikih z blago ali zmerno okvarjenim delovanjem ledvic glejte poglavje 4.2.
For patients with severe renal impairment, see section 4.3. See section 4.2 for information on patients with mild or moderate renal dysfunction.
Za bolnike s hudo okvarjenim delovanjem ledvic glejte poglavje 4.3. Za podatke o bolnikih z blago ali zmerno okvarjenim delovanjem ledvic glejte poglavje 4.2.
For patients with severely reduced liver function a starting dose of 5 mg is recommended.
Pri bolnikih z močno zmanjšanim delovanjem jeter je priporočljiva uporaba začetnega 5-miligramskega odmerka.
For patients with TTP ≥6 months after commencing first-line treatment the HR of OS was 0.86 (95% CI: 0.73 to 1.01), and 0.86 (95% CI: 0.64 to 1.13) in patients with TTP <6 months after commencing first-line treatment.
Pri bolnikih s časom do napredovanja bolezni ≥ 6 mesecev po začetku zdravljenja prve izbire je bil RT za celokupno preživetje 0,86 (95 % IZ: 0,73 do 1,01) in 0,86 (95 % IZ: 0,64 do 1,13) pri bolnikih s časom do napredovanja bolezni < 6 mesecev po začetku zdravljenja prve izbire.
For patients with type 1 diabetes transferring from twice-daily basal insulin or having HbA1c < 8.0% at the time of transfer, the dose of Tresiba needs to be determined on an individual basis.
Pri bolnikih s sladkorno boleznijo tipa 1, ki prehajajo z dvakrat dnevnega odmerjanja bazalnega insulina ali imajo ob prehodu HbA1c < 8,0 %, je treba odmerek zdravila Tresiba določiti individualno.
For patients with type 2 diabetes taking basal, basal-bolus, premix or self-mixed insulin therapy, changing the basal insulin to Tresiba can be done unit-to-unit based on the previous basal insulin dose followed by individual dosage adjustments.
Odmerek bolnikov s sladkorno boleznijo tipa 2, ki prehajajo z bazalnega zdravljenja, bazalno- bolusnega zdravljenja, zdravljenja s pripravljeno mešanico ali mešanico, ki so jo pripravijo sami, lahko pretvorimo v odmerek zdravila Tresiba v razmerju enot ena proti ena glede na prej uporabljani bazalni insulin; odmerek je nato treba individualno prilagoditi.
For patients with unstable angina or myocardial infarction, the recommended dose is 2.5 mg once daily by subcutaneous injection, but the first dose is given intravenously (into a vein) through an existing line or as an infusion (drip) in patients with ST segment elevation.
Za bolnike z nestabilno angino pektoris ali miokardnim infarktom je priporočeni odmerek 2,5 mg enkrat na dan s subkutano injekcijo, pri čemer se prvi odmerek daje intravensko (v veno) skozi obstoječo cevko ali kot infuzijo (kapalno infuzijo) pri bolnikih z dvigom spojnice ST.
For patients with ≥1 relapse in the previous year and ≥9 T2 lesions or ≥1 Gd+ lesion (n=1401), the annual relapse rate at 1 year was 0.39 for placebo, 0.29 for Plegridy every 4 weeks and 0.25 for Plegridy every 2 weeks.
Za bolnike z ≥ 1 recidivom v preteklem letu in ≥ 9 lezij T2 ali ≥1 lezija Gd+ (n = 1.401), letna stopnja recidiva v 1. letu je bila 0,39 za placebo, 0,29 za zdravilo Plegridy vsake 4 tedne in 0,25 za zdravilo Plegridy vsaka 2 tedna.
For patients with ≥2 relapses in the previous year and at least 1 Gd+ lesion (n=273), the annual relapse rate at 1 year was 0.47 for placebo, 0.35 for Plegridy every 4 weeks, and 0.33 for Plegridy every 2 weeks.
Za bolnike z ≥ 2 recidivoma v preteklem letu in vsaj 1 lezijo Gd+ (n = 273), letna stopnja recidiva v letu je bila 0,47 za placebo, 0,35 za zdravilo Plegridy vsake 4 tedne in 0,33 za zdravilo Plegridy vsaka 2 tedna.
For patients without baseline brain metastases, the median IC-TTP was not reached in either the crizotinib (N=132) or the chemotherapy arms (N=131) (HR=0.69 [95% CI: 0.33, 1.45]; 1-sided p-value=0.1617).
Bolniki brez možganskih metastaz ob izhodišču v skupini s krizotinibom (n = 132) ali kemoterapijo (n = 131) niso dosegli mediane IC-TTP (HR = 0,69 (95 % IZ: 0,33, 1,45), 1-stranska vrednost p = 0,1617).
For patients 11 years of age, the initial dose by subcutaneous or intravenous administration is 0.45 µg/kg body weight, as a single injection once weekly.
Za bolnike, stare  11 let, je začetni subkutani ali intravenski odmerek 0,45 µg /kg telesne mase v eni injekciji enkrat na teden.
For PBPC mobilisation in normal donors, filgrastim should be administered at 1.0 MIU (10 μg)/kg/day subcutaneously for 4 to 5 consecutive days.
Za postopek zbiranja matičnih celic iz periferne krvi običajni darovalci 4 do 5 dni zapored prejmejo filgrastim v odmerku 1,0 x 106i.e. (10 μg)/kg/dan v subkutani obliki.
For PBPC mobilisation in normal donors, filgrastim should be administered at 1.0 MU kg/day (10 micrograms/kg/day) for 4 - 5 consecutive days.
Za izplavljanje matičnih celic v periferno kri pri zdravih dajalcih je treba filgrastim 4–5 zaporednih dni uporabljati v odmerku 1,0 M e./kg/dan (10 mikrogramov/kg/dan).
For PBPC mobilisation in normal donors, filgrastim should be administered at 1.0 MU/kg/day (10 micrograms/kg/day) for 4 - 5 consecutive days.
Za izplavljanje matičnih celic v periferno kri pri zdravih dajalcih je treba filgrastim 4–5 zaporednih dni uporabljati v odmerku 1,0 M e./kg/dan (10 mikrogramov/kg/dan).
For PBPC mobilisation in normal donors, Grastofil should be administered at 1.0 MU/kg/day (10 micrograms/kg/day) for 4 - 5 consecutive days.
Za izplavljanje matičnih celic v periferno kri pri zdravih darovalcih je treba Grastofil 4–5 zaporednih dni uporabljati v odmerku 1,0 M e./kg/dan (10 mikrogramov/kg/dan).
For pediatric patients 1-18 years of age, clinical data in paediatric patients has demonstrated that patients receiving r-HuEPO two or three times weekly may be converted to once weekly Nespo, and those receiving r-HuEPO once weekly may be converted to once every other week Nespo.
Za pediatrične bolnike od 1. do 18. leta starosti klinični podatki o pediatričnih bolnikih kažejo, da lahko tisti, ki dobivajo r-HuEPO dva- ali trikrat na teden, preidejo na Nespo enkrat na teden, tisti, ki dobivajo r-HuEPO enkrat na teden, pa na Nespo enkrat vsak drugi teden.
For people who find it hard to take capsules, including very young children, there’s a liquid medicine, Tamiflu oral suspension.
Za ljudi, ki ne morejo zaužiti kapsul, vključno z majhnimi otroki, je na voljo zdravilo v obliki tekočine, Tamiflu peroralna suspenzija.
For people with thrombocytopenia (low blood platelet counts) or any problems with blood clotting, the vaccine should only be injected under the skin to avoid bleeding.
Ljudem s trombocitopenijo (nizko ravnjo trombocitov) ali težavami s strjevanjem krvi je treba cepivo injicirati samo pod kožo, da bi se izognili krvavenju.
For performance of the test, 100 ml 100 % orange juice for patients from the age of 3 to 11 (as a pre- administered test meal), as well as tap water (for dissolving the 13C-urea powder) are necessary.
Da bo test učinkovit, morajo otroci stari 3 – 11 let zaužiti 100 ml 100-% pomarančnega soka (obrok, zaužit pred testom) ter navadno vodo, v kateri raztopimo prašek s 13C-sečnino.
for peripheral neuropathic pain, there were ten studies involving over 3,000 patients, about half of whom had diabetic neuropathy and half of whom had pain following shingles.
v desetih študijah so proučevali periferno nevropatsko bolečino pri več kot 3 000 bolnikih, od katerih jih je približno polovica imela diabetično nevropatijo, druga polovica pa bolečine po pasovcu.
For persistent ALT values ≥10 x ULN discontinue treatment.
Pri dolgotrajno zvišanih vrednostih ALT ≥ 10-krat zgornje referenčne vrednosti (ULN) – prekinitev zdravljenja.
For persistent hypotension, headache, arrhythmia, cardiac, hepatic and renal toxicities the time of injection of the dose of Ceplene should be extended to a maximum of 15 minutes. the dose amount of both Ceplene and IL-2 should be reduced by 20%.
Pri trdovratni hipotenziji, glavobolu, aritmiji, srčni, jetrni in ledvični toksičnosti čas injiciranja odmerka zdravila Ceplene podaljšajte na največ 15 minut; količini odmerkov tako zdravila Ceplene kot IL-2 zmanjšajte za 20 %.
For persistent increases > 3 x ULN (confirmed by repeat testing, see 4.4.), discontinue RoActemra.
V primeru dolgotrajnih zvišanj > 3-kratno ZMN (potrjenih s ponovnim testiranjem, glejte poglavje 4.4) ukinite zdravilo RoActemra.
For persistent increases in this range, interrupt RoActemra until ALT/AST have normalized.
V primeru dolgotrajnih zvišanj v tem razponu prekinite uporabo zdravila RoActemra, dokler se alanin-aminotransferaza (ALT) ali aspartat- aminotransferaza (AST) ne normalizira.
For persistent increases in this range, reduce RoActemra dose to 4 mg/kg or interrupt RoActemra until alanine aminotransferase (ALT) or aspartate aminotransferase (AST) have normalised
V primeru dolgotrajnih zvišanj v tem razponu zmanjšajte odmerek zdravila RoActemra na 4 mg/kg ali prekinite njegovo uporabo, dokler se alanin- aminotransferaza (ALT) ali aspartat-aminotransferaza (AST) ne normalizira.
For Peyronie’s disease, Xiapex breaks down the collagen in the plaque that is causing your erect penis to curve, which may help the previously bent erection to become straighter and enable you to feel less bothered by your disease.
Pri Peyroniejevi bolezni zdravilo Xiapex razgradi kolagen v plaku, ki povzroča ukrivljenost penisa med erekcijo, in lahko pomaga predhodno upognjeni erekciji, da postane bolj ravna, ter lajšanju težav, ki jih bolezen povzroča.
For Peyronie’s disease, Xiapex was compared with placebo in two further studies involving 832 men.
Pri Peyroniejevi bolezni so zdravilo Xiapex primerjali s placebom v dveh dodatnih študijah, v katerih je sodelovalo 832 moških.